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 Introduction 
 Hemolytic uremic syndrome (HUS) is characterized 
by nonimmune microangiopathic hemolytic anemia, 
thrombocytopenia and renal impairment, and it is the 
most common cause of acute renal failure (ARF) in chil-
dren under 4 years of age  [1–3] .
 In the majority of cases (90%), HUS follows an episode 
of gastroenteritis, often with bloody diarrhea (D+HUS), 
triggered by Shiga toxin-producing  Escherichia coli 
(STEC)  [4–6] . Approximately 5–10% of people with diar-
rhea due to STEC  develop HUS  [1] . The remaining 10% 
of cases are classified as atypical because they are not as-
sociated with a prodrome of diarrhea (D–HUS) and can 
be triggered by other bacterial and viral infections (neu-
roaminidase-producing Streptococcus pneumoniae , hu-
man immunodeficiency virus and others)  [1, 7, 8] or can 
be caused by mutations in genes encoding complement 
factor H (CFH), complement factor I (CFI), complement 
factor B, membrane cofactor protein (MCP), complement 
C3 and thrombomodulin  [9–13] .
 Metabolic diseases such as inborn errors of vitamin 
B 12 intracellular metabolism are also associated with neo-
natal or late-onset HUS  [14] , and HUS has also been con-
nected with autoimmune diseases such as LES and an-
tiphospholipid antibodies syndrome  [1] . HUS associated 
with malignancy, transplantation or drugs such as calci-
neurin inhibitors has rarely been reported  [1] .
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 Abstract 
 We retrospectively analyzed etiological, pathological and 
clinical features of the patients with hemolytic uremic syn-
drome (HUS) observed in the Pediatric Nephrology Unit at 
AOU Meyer of Florence. From January 1997 to December 
2008, 22 cases were identified, with an annual incidence of 
0.05 cases per 100,000 inhabitants, and 0.34 cases per 
100,000 children  ! 15 years old. 60% of the patients were D+ 
and 40% were D–, with an age distribution from 12 days to 
13 years. Twenty patients (90%) had oligoanuria, lasting 6.4 
 8 4 days for D+ patients versus 11.8  8 4 days for D– patients. 
The development of chronic kidney disease positively cor-
relates with the initial blood pressure value, the length of 
oligoanuria, and hospitalization. Microbiological investiga-
tions showed an association of D+HUS with different strains 
of Shiga toxin-producing  Escherichia coli in 54% of the cases. 
D–HUS was associated with complement factor H deficiency 
in one patient. In the other cases, the triggering factors were 
pertussis, urinary tract infections and upper airway infec-
tions. While clinical and prognostic features correspond with 
literature data, in Tuscany the annual incidence is lower, and 
the percentage of D–HUS patients is higher than that ob-
served in other studies.  Copyright © 2010 S. Karger AG, Basel 
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 The annual incidence of D+HUS varies in the different 
countries, and meanwhile in western Europe it is 1.5–4 
per 100,000 children aged less than 5 years; in Argentina 
it is in the order of 21.7 per 100,000 children  ! 5 years old 
 [15–18] . In a recent study, performed in Switzerland, the 
annual incidence of HUS was calculated to be 1.42 per 
100,000 children  ^  16 years old  [19] . In France, from 1996 
to 2006, the average annual incidence of HUS was 0.71 
cases per 100,000 children  ! 15 years old and 1.87 cases 
per 100,000 children  ! 5 years old  [17] . In Australia, the 
annual incidence of D+HUS is 0.64 per 100,000 children 
 ! 15 years old and 1.35 per 100,000 children  ! 5 years old 
 [20] ; in the US, the annual incidence of HUS is approxi-
mately 2.2 cases per 100,000 inhabitants with an inci-
dence up to 6.1 cases/100,000 children  ! 5 years old, al-
though for the same group of patients an estimate as low 
as 1.08/100,000 has been provided  [21–23] . In patients 
with diarrhea-associated HUS, the overall mortality rate 
is 3–5%; death or end-stage renal failure occurs in about 
12%, and approximately 25% of survivors demonstrate 
long-term renal sequelae  [1, 6] . Such percentages reach 
30–60% in patients with D–HUS  [10] .
 We performed a retrospective study to analyze epide-
miological, etiological, pathological and clinical fea-
tures of the patients with HUS observed in the Pediatric 
Nephrology Unit at 3rd level Meyer Hospital of Florence 
in Tuscany (Italy). All patients in whom HUS was diag-
nosed in Tuscany were referred to this specialized cen-
tre, except for mild cases, which were treated in local 
hospitals. 
 Patients and Methods 
 We collected the medical records of 22 patients with a diagno-
sis of HUS between January 1997 and December 2008. All the 
patients satisfied the diagnostic criteria for HUS: ARF (increased 
serum creatinine and/or BUN above the limit for age), acute 
Coombs-negative hemolytic anemia (Hb  ! 11 g/dl) with micro-
scopic evidence of fragmented erythrocytes, and thrombocytope-
nia (platelet count  ! 150,000/mm 3 ). 
 Epidemiological data collected included annual incidence, 
seasonal distribution of the cases, sex and age of the patients and 
duration of hospitalization. Clinical data included information 
about prodromal phase and development of the disease, labora-
tory findings and treatment. Biochemical parameters were mea-
sured for all patients by automatic biochemistry analyzer. Micro-
biological investigations were performed both by local laborato-
ries and by the Department of Food Safety and Veterinary Public 
Health of Istituto Superiore di Sanità in Rome, Italy. Genetic anal-
yses (screening for CFH, MCP and CFI mutations), when consid-
ered suitable, were performed by the laboratory of Istituto Mario 
Negri, in Bergamo, Italy. STEC association was determined using 
one of the following criteria: positive stool cultures, evidence of 
Shiga toxin in stools and/or positive serum analysis for LPS anti-
bodies. 
 We performed statistical t test for normally distributed vari-
ables: age of patients, WBC, RBC, platelets, LDH, bilirubin, he-
moglobin, creatinine, BUN, systolic (SBP) and diastolic (DBP) 
blood pressure, duration of oligoanuria and hospitalization. 
 Results 
 Among the 22 patients with a diagnosis of HUS, 14 
were female (64%) and 8 male (36%). All the children were 
in prepubertal age, between 12 days and 13 years of age, 
with an average age of 44  8 39 months. 60% of the pa-
tients were D+, and the average age of these patients was 
35  8 15 months (range 12–54 months). The remaining 
40% were D–, and the average age of these patients was 
53  8 58 months (range 12 days to 13 years).
 Because of the extreme heterogeneity of the age of the 
D– group, the average age in the survey of children with 
D–HUS was not significantly higher than in the survey 
of children with D+HUS (p = 0.3017).
 D+ and D– patients were hospitalized for 18.5  8 5 and 
38  8 14 days, respectively (p = 0.0002).
 The annual average of the cases was 1.7 per year, but 
with a great variability: in 1998, there was a peak of 4 
cases, with no cases in 1999, 2001, 2002 and 2006. The 
monthly distribution of D+HUS peaked during the sum-
mer, with 80% of cases occurring from June to Septem-
ber. There was no difference in seasonal distribution in 
D–HUS cases. The annual incidence was 0.34 cases per 
100,000 children  ! 15 years old and 0.05 cases per 100,000 
inhabitants.
 Clinical characteristics, neurological complications 
and treatment applied are resumed in  table 1 .
 During hospitalization, 20 patients (90%) had oligo-
anuria (diuresis  ! 250 ml/m 2 /24 h –  ! 1 ml/kg/h). 77% of 
the patients presented persistent oligoanuria  for more 
than 5 days, and its duration was significantly longer
(p = 0.008) in D– patients (11.8  8 4 days), compared with 
D+ patients (6.4  8 4 days). During the acute phase of the 
disease, arterial hypertension with SBP and or DBP high-
er than the 95th percentile occurred in 46% (6/13) of D+ 
patients and 66% (6/9) of D– patients. The average SBP was 
112  8 13 (D+) and 136  8 29 mm Hg (D–; p = 0.0266), and 
the average DBP was 69  8 12 (D+) and 82  8 12 mm Hg 
(D–; p = 0.0417). Neurological symptoms, such as drowsi-
ness and seizures, were found in 4 (18%) patients: 2 D+ and 
2 D– patients. 44% of D– patients required pediatric inten-
sive care unit services versus 23% of D+ patients. Among 
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the patients with D+HUS, one developed acute pancreati-
tis. Among the patients with D–HUS, 2 showed unilateral 
renal agenesis with vesicoureteral reflux grade II, and in 
both cases the onset of HUS was a urinary tract infection 
due to no-STEC. Finally, in one case D–HUS was associ-
ated with  Bordetella pertussis infection.
 Dialytic treatment was required by 70% of D+ patients 
and 88% of D– patients. In all the 16 dialyzed patients, 
the duration of oligoanuria was longer than 5 days; 15 
were treated with hemodialysis, one with peritoneal di-
alysis. Blood transfusions were required for all patients; 
only 2 patients received platelet transfusions.
 Fresh frozen plasma (FFP) was administered to 5 chil-
dren with recurrent D–HUS. In 2 cases, FFP was associ-
ated with plasma exchange. The children with no recur-
rences of D–HUS received only symptomatic therapy.
 Among the 5 children with D–HUS recurrence, 3 de-
veloped end-stage renal disease and hypertension during 
the acute phase in spite of the treatment with FFP. Among 
these, one received a successful kidney transplant, one 
died during a combined kidney-liver transplant, one re-
quired chronic dialysis. Finally, one patient developed 
chronic kidney disease (CKD) stage 3, and the renal func-
tion remained normal only in one child with of D–HUS 
recurrence.
 So far, no D+ patients and no children without recur-
rences of D– have either suffered CKD or developed long-
term hypertension.
 The results of microbiological investigations showed a 
D+HUS associated with STEC in 54% of cases. Stool cul-
tures for O157 strain were found positive in 2 patients 
(15%). In 5 children (38%), the infection with different 
strains of E. coli , i.e. O145 (2), O103 (1), O26 (1), O157 (1), 
was demonstrated using serum analysis for antibodies to 
LPS ( table 2 ). 
 In 3 D+HUS patients (23%), despite prodromal diar-
rhea, no microbiological or serologic evidence of STEC 
infections was found. In three D+ cases, stool culture was 
negative but we cannot exclude STEC infection because 
they date back to a time when serum analysis for Shiga 
toxin antibodies was not performed. All D–HUS patients 
were negative for any STEC infection criteria. Nobody 
showed a reduction in the activity of von Willebrand fac-
tor-cleaving protease (VWF-cp) or ADAMTS 13, and no 
patient was found to have inhibitor antibodies against the 
VWF-cp. CFH serum level was within the normal range 
(350–750 mg/l) in all children with D–HUS; a heterozy-
gosis ‘non-sense’ mutation in the CFH gene [(3587 G 1 T) 
in the SCR19–20 region], was found in a patient suffering 
of relapsing severe HUS. Three heterozygosis polymor-
phisms in the CFH gene, associated with a high risk of 
Table 1.  Characteristics of patients with HUS (median 8 SD)
Characteristics All
patients
D+ D– p
value
Sample size 22 (100) 13 (60) 9 (40)
Females 14 (63) 8 (61) 6 (66) 0.8058
Age, months
Median 8 SD
Range
44839
0.44156
35815
12454
53858
0.44156
0.3017
Length of hospital stay, days
Median 8 SD
Range
26814
9460
1885
9430
38814
21460
0.0002
Clinical features at the time of hospitalization
Diarrhea
Bloody diarrhea
Abdominal pain
Pallor
Vomiting 
Fever
13 (60)
9
13 (60)
18 (81)
10 (45)
6 (27)
13 (100)
9 (70)
13 (100)
9 (70)
6 (50)
4 (33)
0
0
0
9 (100)
4 (44)
2 (22)
0.0012
0.0658
0.9369
0.6581
Oligoanuria
Length of oligoanuria
days
20 (90)
885 
11 (84)
6.484
9 (100)
11.884
0.0468
0.008
Hypertension
SBP, mm Hg
DBP, mm Hg
12 (54)
120825
74813
6 (46)
112813
69812
6 (66)
136829
82812
0.3421
0.0266
0.0417
Seizures 4 (18) 2 (15) 2 (22) 0.6827
Intensive care unit 7 (30) 3 (23) 4 (44) 0.2901
Treatment
Dialysis
Blood transfusion 
Platelet infusion
FFP
Plasma exchange
17 (77)
22 (100)
2 (9)
5 (23)
2 (9)
9 (70)
13 (100)
1
0
0
8 (88)
9 (100)
1
5 (55)
2 (22)
0.2794
0.7839
0.0022
0.0746
F igures in parentheses indicate percentages. 
Table 2.  STEC strain detected in D+ patients
STEC strain Cases among D+HUS 
O157 3 (23%)
O145 2 (15%)
O103 1 (8%)
O26 1 (8%)
O111 0 
Microbiologic and
serologic test negative 3 (23%)
Other 3 (23%)
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developing HUS (275 C 1 T, 2089 A 1 G, 2881 G 1 T), were 
found in one patient  [24] . None of our patients had muta-
tions in the MCP gene. In one case, HUS was associated 
with a defect in the activity of the complex II of the mito-
chondrial respiratory chain (succinate coenzyme Q1 re-
ductase) and rhabdomyolysis  [25, 26] .
 The hospital stay and the duration of oligoanuria, SBP, 
DBP, and the development of CKD were significantly 
higher in the D– group (p  ! 0.05). With regard to other 
analyzed parameters, there were no significant differenc-
es between the D+ and D– groups ( table 3 ). The duration 
of oligoanuria and the values of SBP and DBP are posi-
tively correlated with the development of chronic renal 
disease (p  ! 0.05). 
 Discussion 
 Despite its low incidence, HUS it is the primary cause 
of ARF in children between the ages of 1 and 4 years, and 
is the second most common cause in children aged under 
1 or over 4 years. Moreover, it is the seventh cause of CKD 
in children over 5 years  [1] . In Italy, the national annual 
incidence from 1988 to 2004 was 0.28 cases per 100,000 
children  ! 15 years old  [27] , results lower than in other 
European countries  [15–17, 19] . Because risk factors for 
HUS in western European countries show similar fre-
quency and characteristics, the lower incidence of HUS 
observed in Italy might be explained by the difficulty in 
epidemiologic detection of HUS. As far as D+HUS is con-
cerned, Italy has no mandatory notification system for 
either cases of infections caused by STEC O157 or cases 
of HUS; monitoring is therefore achieved via voluntary 
organizations or initiatives, for the most part by The HUS 
National Monitoring System for Pediatric Patients, active 
since 1988. This organization has registered a total of 439 
cases of pediatric HUS between 1988 and 2004  [27] . The 
absence of mandatory notification of HUS and/or  E. coli 
infection holds up epidemiological studies, especially in 
Italy, where the regional organization of health facilities 
represents an additional obstacle. In fact, the practice of 
notification may differ from a geographic area to another. 
In our study, the annual incidence of HUS in Tuscany is 
0.05 cases per 100,000 inhabitants and 0.34 cases per 
100,000 children  ! 15 years old. The incidence of HUS in 
Tuscany is higher than the national annual incidence but 
lower than in other countries and, in some years, no cas-
es have been observed, probably due to the rarity of the 
disease and to environmental factors difficult to deci-
pher. Considering cattle as a major reservoir of STEC 
pathogenic for humans and comparing the HUS inci-
dence in Tuscany to other European countries, the differ-
ence can be related to the low presence of cattle breeding 
in Tuscany  [28] . Besides, we have to consider that many 
D+HUS cases were probably treated in local hospitals and 
not in our Nephrology Unit, because they were mild 
forms, and thus we did not gain knowledge of them. In 
1998, in Tuscany, the pediatric units of all hospitals estab-
lished a network that allows cultural exchanges and eas-
ier diagnosis. This network makes it also possible to treat 
some mild renal diseases in hospitals without pediatric 
nephrology facilities. It is, however, possible that many 
mild cases are undiagnosed, because oligoanuria and re-
nal failure are explained as due to post-diarrhea dehydra-
tion. Furthermore, rehydration performed in a periph-
eral hospital, might prevent severe HUS, as recent data 
suggest  [29] . These considerations also help explain the 
higher percentage of D–HUS patients in our series com-
pared to the series in other studies. In fact, in the 12-year 
span of our survey, the percentage of D+ patients was 
60%, versus 40% for D– patients. On the other hand,
in other studies, the proportions are very different, rang-
ing between 90 and 97% for D+HUS and 3 and 10% for 
D–HUS  [1, 15–17] . STEC infection can manifest without 
diarrhea, leaving HUS to be classified as D–, even though 
it is actually an undetected D+ form. In fact, one of the 
largest multicenter studies demonstrated that 50% of
D–HUS cases showed evidence of STEC infection from 
microbiological and/or serological investigations  [16, 30] . 
However, even if in the 3 oldest cases of our series, sero-
logical investigations for STEC infection were not avail-
able and the assignment to the D–HUS group is uncer-
tain, the percentage of D–HUS remains 25%. In the US 
and Europe,  E. coli O157 is the principal cause of D+HUS, 
both for sporadic cases and epidemics  [4, 15–17, 30] . In 
other parts of the world, for example in Australia, infec-
tions from non-O157 strains have been more frequently 
Table 3.  Laboratory findings at admission
Parameters D+ D– p value
White cell count, !103/mm3 1686.6 27.2826.9 0.1816
Red cell count, !103/mm3 3,1218990 2,6528584 0.5569
Platelet count, !103/mm3 66.1850.8 55.8839.4 0.3572
Hemoglobin, g/dl 8.682.3 7.181.5 0.5159
LDH, U/l 4,62682,934 4,97582,364 0.9405
Serum creatinine, mg/dl 3.683.1 2.382.1 0.4516
Bilirubin, mg/dl 1.880.8 3.681.8 0.0675
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reported, especially O111  [20] . The cause of these varia-
tions in the distribution of the serotypes in various areas 
and countries has not yet been clarified. In our survey, 
only 23% of patients with diarrhea resulted positive for 
the O157 strain, whereas 30% resulted positive for non-
O157 STEC strains, which further confirms the territo-
rial variability of the diffusion of STEC.
 The German and Italian studies report a larger inci-
dence of infection from non-O157 STEC in the youngest 
children  [16, 30] ; among our patients we have not ob-
served that, because the children with evidence of a non-
O157 STEC infection are not different in age to those of 
the group infected with O157 STEC.
 The traditional stool culture  appears to be ineffective 
in the diagnosis, as it resulted positive in only 2 cases 
(17%). This is mainly due to the short time span during 
which it is possible to find the bacteria in the feces, and 
to the fact that often the stool culture is necessarily made 
5–7 days after the first appearance of diarrhea. Further-
more, it is clear that research into the emerging problem 
of non-O157 STEC strains is essential, as our study also 
confirmed. 
 In accordance with the literature data, the average age 
was higher in the D– group (53.1  8 58 months) than in 
the D+ group (35.1  8 15 months), with an extreme het-
erogeneity of age of D– children ( table 1 ), which ranged 
from 12 days to 13 years, whereas almost all D+ patients 
were in the age range of  ! 4 years. 
 The widened age range at the appearance of D–HUS 
is already known  [4] and is due to the presence of patients 
both with the onset of disease in the first months of life 
and in adolescent or adult patients. 
 Genetic factors play a considerable role in D– HUS. 
CFH or CFI mutations carriers often develop the disease 
before 3 months of age, while patients with MCP muta-
tions develop it later in life  [9] . So we might hypothesize 
that mutations in different genes involved in D–HUS can 
influence the age at onset. On the other hand, the pene-
trance of HUS among CFH, MCP and CFI mutations car-
riers appears to be between 40 and 50% and, even in pa-
tients with multiple genetic risk factors, the syndrome 
might not occur until middle age  [9, 10] . Moreover, the 
newborns present an increased risk of Gram-negative sep-
sis and endothelial toxic damage with secondary HUS.
 Even in our series, the time of hospitalization and re-
covery was significantly higher in D– patients (38  8 14 
days) than in D+ patients (18  8 5 days), due to a greater 
overall seriousness of the disease. The average duration 
of hospitalization in D+HUS was similar to that observed 
in a similar survey  [31] , but in the French study, the aver-
age duration of hospitalization for D+ patients was 10 
days  [17] . This might be due to differences in patient man-
agement or, more likely, to a greater complexity of cases 
under our observation in a 3rd level pediatric hospital.
 According to other epidemiological reports, most of 
the D+HUS cases (83%) manifest during the summer 
months, whereas no seasonal fluctuation was detected for 
the D– cases  [4, 5, 16, 17] . In our study, the duration of 
oligoanuria and the values of SBP and DBP were posi-
tively correlated with the development of CKD (p  ! 0.05) 
and were considerably higher in D–HUS patients. A re-
cent retrospective study demonstrated that the preva-
lence of long-term renal damage in D+HUS rises as the 
duration of oligoanuria increases, and is considerably less 
among patients who had oligoanuria for less than 5 days 
compared to those who had oligoanuria for more than 10 
days  [32, 33] . However, none of our D+ patients with oli-
goanuria lasting more than 5 days developed long-term 
renal damage. 
 Treatment of STEC associated with HUS consists of 
the management of ARF and its complications; mean-
while, D–HUS treatment should be related to etiology 
 [34] . The German study reported that 61% of patients re-
ceived dialysis treatment, 75% RBC transfusions, 16% 
platelet transfusions, and 9% plasmapheresis. The Amer-
ican study, including only D+HUS cases, reported that 
55% of subjects needed dialysis, and 37% RBC transfu-
sions  [16, 21] . Among our D+HUS patients, dialysis was 
given to 75%, RBC transfusion to 100%, while only 2 re-
ceived platelet transfusion. So, comparing our data with 
those of the other series, the percentage of patients re-
quiring dialysis and RBC transfusions was higher, and 
this seems to support the thesis that the cases under our 
observation were actually characterized by more severe 
clinical manifestations. 
 In conclusion, despite the low number of our patients, 
our study verified important epidemiological, etiological 
and clinical features of HUS in Tuscany. The salient 
points are the high percentage of D–HUS patients, the 
low percentage of O157 STEC strain and, despite the se-
verity of HUS among many patients, no death occurred 
during the acute phase of disease. In order to get more 
epidemiological, clinical, prognostic and therapeutic in-
formation, to guarantee greater reliability in terms of sta-
tistical estimation, and to correct the probable underes-
timation of the disease, it would be useful if HUS notifi-
cation became mandatory and if a regional register of the 
disease was created, where the patients’ clinical data and 
disease course could be recorded.
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